See more : Mangalam Drugs & Organics Limited (MANGALAM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Scopus BioPharma Inc. (SCPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scopus BioPharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- 26 Capital Acquisition Corp. (ADERU) Income Statement Analysis – Financial Results
- ALNA TRADING & EXPORTS LTD. (ALNATRD.BO) Income Statement Analysis – Financial Results
- Terex Corporation (TEX) Income Statement Analysis – Financial Results
- SiriusPoint Ltd. (SPNT-PB) Income Statement Analysis – Financial Results
- Malacca Straits Acquisition Company Limited (MLAC) Income Statement Analysis – Financial Results
Scopus BioPharma Inc. (SCPS)
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.68M | 15.02M | 7.42M | 463.11K | 277.54K |
| General & Administrative | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Cost & Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 774.68K | 706.45K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73K | 1.50K | 1.44K | 664.00 | 161.14K |
| EBITDA | -11.71M | -27.63M | -10.15M | -2.69M | -685.96K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.71M | -27.63M | -10.16M | -2.69M | -685.96K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 681.21K | -706.45K | 0.00 | 0.00 |
| Income Before Tax | -11.71M | -26.95M | -10.86M | -2.69M | -685.96K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -105.05K | 774.68K | 706.45K | 1.00 | -847.11K |
| Net Income | -11.61M | -27.73M | -11.57M | -2.69M | -685.96K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| EPS Diluted | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| Weighted Avg Shares Out | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
| Weighted Avg Shares Out (Dil) | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Scopus BioPharma Launches Duet Therapeutics
5 Best Penny Stocks To Buy Right Now According To Insiders
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
Source: https://incomestatements.info
Category: Stock Reports